Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Alzamend Neuro, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Dr. Lynne Fahey McGrath, a board director since Alzamend Neuro's June 2021 IPO, passed away on July 20, 2026. This represents a loss of experienced biopharmaceutical sector expertise and strategic guidance for the emerging growth company.
Key Takeaways
Dr. Lynne Fahey McGrath, who served as a director since the company's IPO in June 2021, passed away on July 20, 2026
Chairman William B. Horne emphasized Dr. McGrath's significant contributions to the company's strategy and governance
2 more takeaways